---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-004799"
form_type: "8-K"
ticker: "BTCY"
cik: "0001630113"
company_name: "BIOTRICITY INC."
filed_at: "2022-02-16T23:59:59+00:00"
generated_at: "2026-06-27T07:32:10.357692+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biotricity Q3 FY22 revenue $1.93M (+93% YoY); net loss $7.34M, cash $16.8M

## Summary
- Revenue of $1.93M, up 93% YoY and 7% sequentially; SG&A rose only 40%.
- Net loss $7.34M ($0.15/share); adjusted net loss $6.0M ($0.12/share) excluding $1.34M derivative expenses.
- Cash position of $16.8M at quarter-end is the highest ever; completed $12M non-dilutive debt financing.
- FDA clearance of Biotres expands TAM from $1B to $5.7B; Bioheart direct-to-consumer launched at $199.
- Company reiterates expectation for full-year triple-digit revenue growth.

## SEC filing metadata
- accession: 0001493152-22-004799
- form_type: 8-K
- ticker: BTCY
- cik: 0001630113
- company_name: BIOTRICITY INC.
- filed_at: 2022-02-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630113/000149315222004799/0001493152-22-004799-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630113/000149315222004799/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-004799
- JSON: https://secwatch.observer/filing/0001493152-22-004799.json
- Plain text: https://secwatch.observer/filing/0001493152-22-004799.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.